Your donation will make a difference:
Cystic Fibrosis Trust

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy


Therapeutic category
the type of treatment or therapy being studied. A therapy could range from a medication addressing a particular characteristic of CF to a device or activity e.g. exercise

Restore CFTR Function

Trial status

Closed to recruitment - in follow up

Participating Centres
the different stages involved in the development of a new medication. Phase I focuses on initial safety in people. Phase 2 evaluates safety, correct dose and early signs of whether the medication works. Phase 3 is the stage before medication licensing and looks at safety and medication effectiveness. Phase 4 evaluates longer term use of a medication after it has been licensed for use

Phase I

Full title

A Phase I, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis.

The single treatment group will enroll adult subjects with CF currently on stable KALYDECO® background therapy for a minimum of 3 months at the time of randomization. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 14 Days. The subjects will continue treatment with KALYDECO® throughout the study.

Trial Reference Number


Trial type


Length of participation
the length of time a participant will take part in a trial, from the first to the last appointment

21 weeks

the name of the treatment or therapy being researched


Recruitment target
the number of participants who need to be recruited for the trial in the UK


Last edited date

16 March 2018

CF sponsor

Proteostasis Therapeutics, Inc.

CF sponsor type


Who can take part?



Top inclusion criteria
  • Stable on Kalydeco dosing for both label indication and per label dosing for a minimum of 3 months at the time of randomization.
  • Non-smoker and non-tobacco user for a minimum of 30 days prior to screening and for the duration of the study.
  • Confirmed diagnosis of CF.
Top exclusion criteria
  • Participation in another clinical trial or treatment with an investigational agent within 30 days.
  • History of organ transplantation.
  • Male and female of child-bearing potential, unless they are using highly effective methods of contraception during participation in the clinical study and for 4 weeks after termination from study.

CF centres running this trial


Celerion Research Institute


22-24 Lisburn Rd Belfast BT9 6AD

Recruitment starts

July 2017

Recruitment ends

February 2018


Downey, Damian

Get in touch


Medicines Evaluation Unit


The Langley Building Southmoor Road Wythenshawe Manchester M23 9QZ

Recruitment ends

February 2018


Downey, Damian

Get in touch